Key result
COVID-19 infection increases myocarditis risk ~16-fold, far exceeding rates seen with mRNA vaccination.
Why the study?
The epidemiology and prognosis of myocarditis related to COVID-19 are unknown, and the risk of myocarditis secondary to vaccination requires consideration in the context of global vaccine benefits.
This narrative review summarizes the etiopathogenesis, epidemiology, clinical manifestations, diagnosis, prognosis, and treatment of myocarditis related to COVID-19 and mRNA vaccines.
Answers are grounded in this paper and cite their sources.
Informs individualized myocarditis risk discussions for mRNA vaccination in males 12-17; leaves open need for prospective comparative studies.
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
No takes yet. Share an insight, caveat, or question.
Molina-Ramos et al. (2022) conducted a review in Myocarditis related to COVID-19 and SARS-CoV-2 vaccination. SARS-CoV-2 infection and mRNA COVID-19 vaccination was evaluated. COVID-19 infection increases myocarditis risk 16-fold (~150 per 100,000), while mRNA vaccination carries a lower myopericarditis rate (56-69 per million in males aged 12-17).
Synapse has enriched 10 related papers. Consider them for comparative context: